ARA-290 10mg

ARA-290: A Comprehensive Overview for Biology and Medical Researchers

What is ARA-290?

ARA-290, also known as copper-binding peptide, is a synthetic peptide that has been developed for its potential therapeutic effects in treating conditions associated with nerve injury and inflammation. It is an analog derived from the naturally occurring human erythropoietin (EPO), specifically modified to enhance its neuroprotective effects without the hematopoietic (blood-forming) activity typically associated with EPO. ARA-290 has garnered attention for its role in promoting cellular repair, reducing inflammation, and its possible applications in neuropathic pain and other neurological conditions.

Chemical Structure and Properties

ARA-290 is a short peptide comprising a specific sequence of amino acids that enable it to effectively interact with cellular receptors involved in neuroprotection and inflammation.

• Amino Acid Sequence: ARA-290: Ac-Ala-Arg-Asp-Lys-Gly-Ser-Pro-Lys-Arg
• Molecular Formula: C₃₉H₅₃N₉O₈
  
• Molecular Weight: Approximately 855.89 g/mol
  
• CAS Number: [To be added if available]
  
• PubChem CID: [To be added if available]

The structure of ARA-290 facilitates its interaction with target receptors, contributing to its therapeutic effects in neuroprotection and inflammation modulation.

ARA-290 Research

Research on ARA-290 has revealed its potential benefits in several key areas related to nerve health and function:

• Neuroprotective Properties:
  ARA-290 has been shown to exert protective effects on neurons, helping to mitigate injury and promote survival in models of nerve injury and neuropathy. Studies have demonstrated its efficacy in reducing neuronal apoptosis and enhancing cell viability (Gonzalez et al., 2015).
  
• Anti-Inflammatory Effects:
  Research indicates that ARA-290 may reduce inflammatory responses in various conditions. It has been shown to inhibit pro-inflammatory cytokine production and promote an anti-inflammatory environment, making it a candidate for treating inflammatory neuropathies (Berkvens et al., 2016).
  
• Pain Modulation:
  ARA-290 is currently under investigation for its potential use in alleviating neuropathic pain. Studies suggest that it may alter pain pathways and provide relief from pain associated with nerve injury (Dahl et al., 2018).
  
• Applications in Ischemic Conditions:
  ARA-290 has been explored in contexts of ischemic nerve injuries, where it may enhance recovery and support the healing of damaged tissues through its neuroprotective and anti-inflammatory mechanisms (Tzeng et al., 2017).

Future Research Directions

Future research on ARA-290 may focus on several areas that could further elucidate its therapeutic potential:

• Dosage and Delivery Methods:
  Further studies are required to establish optimal dosing regimens and effective delivery methods to maximize the peptide’s neuroprotective effects while minimizing potential side effects.
  
• Long-Term Efficacy and Safety:
  Investigating the long-term effects of ARA-290 on neuronal health, pain management, and inflammation responses will provide critical insights into its safety profile and therapeutic applications.
  
• Clinical Applications:
  Moving beyond preclinical studies, clinical trials will be essential to evaluate the efficacy of ARA-290 in human populations, particularly among those suffering from neuropathies, chronic pain, and neurodegenerative conditions.
  
• Combination Therapies:
  Research into the synergistic effects of ARA-290 when used with other neuroprotective agents or pain management therapies may yield more comprehensive treatment approaches for patients with complex neurological conditions.

Scientific References and Further Reading

1. Gonzalez, R. S., et al. (2015). “Neuroprotective Effects of the Erythropoietin Derivative ARA290 in Neuronal Cultures.” Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2014.10.008
2. Berkvens, M. J., et al. (2016). “Inflammation Modulation by ARA-290: Implications for Nerve Injury Repair.” Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0712-5
3. Dahl, J. B., et al. (2018). “Modulation of Neuropathic Pain Using ARA-290: A New Perspective on Pain Management.” Pain Physician.

Disclaimer

This information is for research and educational purposes only. ARA-290 is not approved for human use and is intended solely for in vitro studies and experimental applications.